BioSpect
the business of Bi
24 years of leveraging the business of Bio
www.biospectrumindia.co

PerkinElmer joins Accenture's Life Sciences Ecosystem for research and innovation in drug discovery

21 April 2019 | News

Joining the ecosystem is in sync with PerkinElmerâ??s strategy to deliver advanced informatics solutions that empower researchers to more quickly and easily spotlight key findings amidst the ever-growing volume, types and complexity of scientific big data.

PerkinElmer, a global leader committed to innovating for a healthier world has announced that it has joined Accenture's open partner ecosystem, designed to help solution providers, software vendors and life sciences companies team more effectively to accelerate drug discovery and improve patient outcomes.

The ecosystem is an integral part of Accenture's cloud-based informatics research platform focused on improving productivity, efficiency and innovation in the drug discovery process. Accenture is currently working with a select number of independent software vendors and organizations, including PerkinElmer, to integrate their technology and content into Accenture's research platform.

Joining the ecosystem is in sync with PerkinElmer's strategy to deliver advanced informatics solutions that empower researchers to more quickly and easily spotlight key findings amidst the ever-growing volume, types and complexity of scientific big data.

PerkinElmer is making its informatics solutions compatible with Accenture's integrated ecosystem starting with the following: key functionality of electronic laboratory notebooks, which allow for effective organization and sharing of experimental data; TIBCO Spotfire software for data visualization in research and clinical analytics; and ChemDraw software, a leading application for chemistry-based analytics and workflows. PerkinElmer Signals solutions, which provide advanced analytics for R&D such as lead discovery and translational medicine, are also planned to be available via the Accenture ecosystem in the future.

"Today's pharmaceutical companies are dealing with tremendous silos of data that are hard to access, expensive to maintain and can create missed opportunities to connect insights that propel new patient therapies," said David Wang, general manager of Informatics at PerkinElmer. "Forward-looking life science organizations are reimagining, streamlining and accelerating the power of their research organizations by digitizing and integrating their big data. This is the promise of informatics in the lab, and we are pleased to be the largest instrument and informatics solution provider to join the Accenture ecosystem to date."

"As PerkinElmer is a leading provider of lab instrument and informatics solutions, we're pleased to welcome the company to Accenture's open partner ecosystem and to be working closely with them to integrate their capabilities into our cloud-based research platform," said Joe Donahue, a managing director in Accenture's Life Sciences practice. "Our clients will benefit from access to PerkinElmer's solutions and we look forward to collaborating with them to help our mutual clients gain insights from data to drive scientific discovery—ultimately improving patient outcomes."